Clinical pharmacology of oral anticoagulants in patients with kidney disease

N Jain, RF Reilly - Clinical Journal of the American Society of …, 2019 - journals.lww.com
Oral anticoagulants are commonly used drugs in patients with CKD and patients with ESKD
to treat atrial fibrillation to reduce stroke and systemic embolism. Some of these drugs are …

Apixaban Use in Patients with Kidney Impairment: A Review of Pharmacokinetic, Interventional, and Observational Study Data

SR Mandt, N Thadathil, C Klem, C Russ… - American Journal of …, 2024 - Springer
Chronic kidney disease (CKD) remains a significant global health issue and is a leading
cause of mortality worldwide. Patients with CKD have an increased risk of developing atrial …

Safety and efficacy of apixaban versus warfarin in patients with end‐stage renal disease: meta‐analysis

R Chokesuwattanaskul… - Pacing and Clinical …, 2018 - Wiley Online Library
Background At the present, apixaban is the only nonvitamin K oral anticoagulant approved
by the Food and Drug Administration for use with patients with creatinine clearance< 15 …

[HTML][HTML] Safety and effectiveness of apixaban compared to warfarin in dialysis patients

D Reed, S Palkimas, R Hockman, S Abraham… - Research and Practice …, 2018 - Elsevier
Essentials• The safety of apixaban in patients on dialysis is currently debated.• Bleeding
events were retrospectively compared for dialysis patients on warfarin vs apixaban.• Overall …

Effect of rivaroxaban or apixaban in atrial fibrillation patients with stage 4–5 chronic kidney disease or on dialysis

C Chen, Y Cao, Y Zheng, Y Dong, J Ma, W Zhu… - … Drugs and Therapy, 2021 - Springer
Background Anticoagulant treatment in non-valvular atrial fibrillation (AF) patients with
severe chronic kidney disease (CKD) or on dialysis remains a matter of debate. The object …

[HTML][HTML] Anticoagulation in patients with end-stage renal disease and atrial fibrillation: confusion, concerns and consequences

N Goel, D Jain, DB Haddad, D Shanbhogue - Journal of Stroke, 2020 - ncbi.nlm.nih.gov
End-stage renal disease (ESRD) patients have a higher prevalence of diabetes mellitus,
hypertension, congestive heart failure and advanced age, along with an increased …

Evaluation of standard versus reduced dose apixaban for the treatment of venous thromboembolism in patients with severe renal disease (ESRD-VTE)

P Knueppel, SH Bang, C Troyer, A Barriga, J Shin… - Thrombosis research, 2022 - Elsevier
Background There are no clear dosing recommendations when using apixaban for venous
thromboembolism (VTE) treatment in patients with severe or end-stage renal disease; …

Evaluation of outcomes with apixaban use for venous thromboembolism in hospitalized patients with end-stage renal disease receiving renal replacement therapy

J Chen, S Nguyen, M Ruegger, L Samuel… - Journal of Thrombosis …, 2022 - Springer
While direct oral anticoagulants (DOACs) received expanded labeling for use in atrial
fibrillation (AF) for end-stage renal disease (ESRD) based on pharmacokinetic trials, little …

Direct oral anticoagulants in end-stage renal disease

AJ Klil-Drori, V Tagalakis - Seminars in thrombosis and …, 2018 - thieme-connect.com
Patients with end-stage renal disease (ESRD) were excluded from pivotal clinical trials with
oral anticoagulants. While such patients are at an increased risk of venous and arterial …

Factor Xa Inhibitors Versus Vitamin K Antagonists in Atrial Fibrillation Patients with End-Stage Kidney Disease on Dialysis: A Meta-Analysis

M Xiong, L Guo, Y Wan - Clinical and Applied Thrombosis …, 2024 - journals.sagepub.com
Background Atrial fibrillation (AF) is prevalent among patients with end-stage kidney disease
(ESKD) undergoing dialysis, and both conditions are associated with a heightened risk of …